Aridis Pharmaceuticals’ (NASDAQ:ARDS) lock-up period is set to expire on Monday, February 11th. Aridis Pharmaceuticals had issued 2,000,000 shares in its public offering on August 14th. The total size of the offering was $26,000,000 based on an initial share price of $13.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the expiration of the lock-up period.
Several brokerages have weighed in on ARDS. Maxim Group set a $25.00 price objective on Aridis Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, November 13th. Zacks Investment Research raised Aridis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a report on Tuesday, November 13th. Cantor Fitzgerald reissued a “buy” rating and set a $25.00 price objective on shares of Aridis Pharmaceuticals in a report on Tuesday, November 13th. Finally, ValuEngine lowered Aridis Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, December 21st. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $25.40.
NASDAQ:ARDS opened at $8.55 on Friday. Aridis Pharmaceuticals has a 1 year low of $7.59 and a 1 year high of $13.85.
Aridis Pharmaceuticals (NASDAQ:ARDS) last posted its earnings results on Tuesday, November 13th. The company reported ($1.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.05) by ($0.92). The business had revenue of $1.02 million during the quarter, compared to analysts’ expectations of $0.33 million. Sell-side analysts predict that Aridis Pharmaceuticals will post -4.2 earnings per share for the current year.
Aridis Pharmaceuticals Company Profile
Aridis Pharmaceuticals Inc, a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S.
Further Reading: Coverage Ratio
Receive News & Ratings for Aridis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aridis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.